PUBLISHER: The Business Research Company | PRODUCT CODE: 1751010
PUBLISHER: The Business Research Company | PRODUCT CODE: 1751010
Gut microbiota refers to the diverse community of microorganisms, including bacteria, viruses, fungi, and other microbes, that inhabit the gastrointestinal tract. These microbes play a crucial role in digestion, immune function, and overall health by influencing metabolism and offering protection against harmful pathogens.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary product types in the gut microbiota market include prebiotics, probiotics, drugs, supplements, and other products. Prebiotics are non-digestible food components, mainly dietary fibers, that serve as food for beneficial bacteria in the gut. These products are distributed through various channels such as pharmacies, drugstores, online retail, health food stores, supermarkets, hypermarkets, and specialty stores. They are used for a range of applications including digestive health, immune health, weight management, mental health, and cardiovascular health, and cater to different end-users, including adults, children, and the elderly.
The gut microbiota market research report is one of a series of new reports from The Business Research Company that provides gut microbiota market statistics, including gut microbiota industry global market size, regional shares, competitors with a gut microbiota market share, detailed gut microbiota market segments, market trends and opportunities, and any further data you may need to thrive in the gut microbiota industry. This gut microbiota market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The gut microbiota market size has grown rapidly in recent years. It will grow from$0.55 billion in 2024 to $0.65 billion in 2025 at a compound annual growth rate (CAGR) of 18.5%. The growth during the historic period can be attributed to the discovery of probiotics and prebiotics, the rise in gastrointestinal disorders, increasing interest in functional foods, the growing use of antibiotics, and heightened awareness of the gut-brain axis.
The gut microbiota market size is expected to see rapid growth in the next few years. It will grow to$1.27 billion in 2029 at a compound annual growth rate (CAGR) of 18.2%. The growth in the forecast period can be attributed to the expansion of personalized nutrition, rising demand for microbiome-based therapeutics, growth in functional and fermented foods, and regulatory support for probiotics and prebiotics. Major trends in the forecast period include AI-driven microbiome analysis, advancements in next-generation sequencing, CRISPR-based gut microbiota editing, development of smart probiotic delivery systems, and the emergence of wearable gut health monitoring devices.
The increasing demand for personalized medicine is expected to drive the growth of the gut microbiota market in the coming years. Personalized medicine involves tailoring treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize health outcomes and improve care. The demand for personalized medicine is growing as advancements in genomics and biotechnology enable more precise identification of genetic profiles, allowing for treatments that are better targeted, more effective, and have fewer side effects. Personalized medicine is particularly beneficial for gut microbiota, as it allows for the customization of treatments based on an individual's unique microbiome composition, optimizing gut health and improving outcomes for digestive and metabolic disorders. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a significant increase compared to the 12 approvals in 2022. As such, the growing demand for personalized medicine is driving the expansion of the gut microbiota market.
Leading companies in the gut microbiota market are focusing on innovative solutions, such as orally administered fecal microbiota, to address various gastrointestinal diseases and disorders. Orally administered fecal microbiota involves taking a capsule or pill containing beneficial bacteria from a healthy donor's stool to restore balance to the gut microbiome. For example, in April 2023, Seres Therapeutics Inc., a US-based microbiome therapeutics platform company, received FDA approval for Vowst, the first oral fecal microbiota product designed to prevent recurrent Clostridioides difficile (C. difficile) infection (CDI) in adults aged 18 and older. Vowst is intended for use after antibacterial treatment for recurrent CDI, providing a more accessible, patient-friendly alternative to traditional fecal microbiota transplants, which are usually administered via colonoscopy or enema. The oral formulation of Vowst may improve treatment adherence and promote the broader adoption of microbiome-based therapies in healthcare.
In April 2023, Archer-Daniels-Midland Company (ADM), a US-based food processing company, partnered with Brightseed to develop scientifically backed synbiotic products that support gut microbiome health. This collaboration leverages Brightseed's AI-driven molecular insights to create evidence-based formulations that aim to enhance immune function, metabolic health, and mental well-being. By combining ADM's nutrition expertise with Brightseed's AI technology, the partnership is focused on advancing gut health solutions grounded in cutting-edge science. Brightseed, a US-based biotechnology company, specializes in gut microbiome research through its proprietary AI platform.
Major players in the gut microbiota market are Danone S.A., DuPont de Nemours Inc., International Flavors & Fragrances Inc., Seres Therapeutics, Yakult Honsha Co. Ltd., Chr. Hansen Holding A/S, Lallemand Inc., Lifeway Foods Inc., BioGaia AB, Probi AB, Seed Health, Enterome, Vedanta Biosciences Inc., Evolve BioSystems Inc., Winclove Probiotics B.V., Kallyope Inc., Sun Genomics Inc., Synlogic Inc., OpenBiome, and Codex Labs Corp.
North America was the largest region in the gut microbiota market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gut microbiota report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the gut microbiota market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The gut microbiota market consists of sales of postbiotics, personalized nutrition products, and fecal microbiota transplantation (FMT) preparations. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Gut Microbiota Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on gut microbiota market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for gut microbiota ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gut microbiota market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.